Search - tctmd.com

Displaying 121 - 140 of 284

Sort: Relevancy | Date

News Daily News

PAD Significantly Ups Morbidity and Mortality in AMICS

L.A. McKeown

March 29, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

Fewer Diabetic Complications Seen When NOACs Given for AF

L.A. McKeown

February 22, 2022

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Daily News

Study Touts Benefits of Exercise as Primary CVD Prevention in Older Adults

L.A. McKeown

February 15, 2022

News Daily News

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Michael O'Riordan

January 25, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

Risk Factors Still Matter for Patients With Zero CAC Score: MESA

Yael L. Maxwell

December 14, 2021

News Daily News

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Michael O'Riordan

December 09, 2021

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Conference News TCT 2021

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

L.A. McKeown

October 22, 2021

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

News Opinion CV Team Dispatch

September 2021 News Roundup

L.A. McKeown

September 01, 2021

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

L.A. McKeown

August 10, 2021

News Daily News

Coffee Doesn’t Disturb Heart Rhythm: UK Biobank Analysis

Caitlin E. Cox

July 22, 2021

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

Advertisement

PAD Significantly Ups Morbidity and Mortality in AMICS

March 2022 News Roundup

Fewer Diabetic Complications Seen When NOACs Given for AF

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Study Touts Benefits of Exercise as Primary CVD Prevention in Older Adults

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Risk Factors Still Matter for Patients With Zero CAC Score: MESA

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

November 2021 News Roundup

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

September 2021 News Roundup

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

Coffee Doesn’t Disturb Heart Rhythm: UK Biobank Analysis

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content